Rain Therapeutics to Report Second Quarter 2021 Financial Results and Highlights of Recent Progress on August 10, 2021
Rain Therapeutics Inc. (NasdaqGS: RAIN) is set to release its second-quarter financial results on August 10, 2021. The management will host a conference call at 1:30 PM PT to discuss the financial outcomes and business developments. Rain Therapeutics focuses on precision oncology therapies, utilizing a tumor-agnostic strategy to select patients based on genetic profiles, with its leading candidate being milademetan (RAIN-32), an MDM2 inhibitor. Investors and stakeholders can participate in the call via dial-in or a webcast link provided in the announcement.
- Company scheduled to discuss second-quarter results on August 10, 2021, indicating transparency.
- Lead product candidate, milademetan, targets oncogenic drivers effectively.
- None.
NEWARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN) a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the second quarter that ended June 30, 2021 and highlights of recent progress, on Tuesday, August 10, 2021. On that day, management will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss the Company’s business and financial results.
Conference Call and Webcast Details:
Date: August 10, 2021
Time: 1:30 p.m. PT (4:30 p.m. ET)
Dial In Numbers: 1 (800) 708-4539 (U.S. Toll Free) / 1 (847) 619-6396 (U.S. Toll)
Passcode: 50202648
Webcast Link: https://edge.media-server.com/mmc/p/4ar5rh24
The call will be recorded and available for replay on the Company’s website for approximately 30 days after the call.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan (RAIN-32), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. For more information, visit www.rainthera.com.
Media Contact for Rain:
Grace Fotiades
LifeSci Communications
+1.646.876.5026
gfotiades@lifescicomms.com
FAQ
When will Rain Therapeutics report its second-quarter results?
What is the purpose of the conference call on August 10, 2021?
What is Rain Therapeutics' lead product candidate?
How can I access the conference call by Rain Therapeutics?
